On the second Thursday in June, Global Fatty Liver Day brings overdue attention to one of the most widespread yet overlooked public health threats of our time: fatty liver disease.
Letters from the Director Archive
Employer Insurance Coverage of Obesity Treatment
Limitations in access and coverage of obesity medications has paralleled the advances in the usage of GLP-1s.
Guest Letter: Concerns About Compounded GLP-1 Medications
OAC has long advised our members against using compounded GLP-1’s. The main reason is FDA’s own words about compounding.
FDA's New Draft Guidance for Obesity Medications
This past January the FDA published a draft guidance entitled “Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction.”
OCW's theme this year is “Commit to Care,” to encourage everyone to advocate for accessible, affordable, respectful, and compassionate obesity care.
Lancet Commission Report on Clinical Obesity
On January 14th, the Lancet Diabetes and Endocrinology Global Commission released a report on the definition and diagnostic criteria of clinical obesity.
CMS Proposes Rule to Cover Obesity Medications
In late November, the Centers for Medicare and Medicaid Services (CMS) officially proposed a rule to cover obesity medications in Medicare and Medicaid.
The Impact of Rising Rates of Obesity and Diabetes
November was National Diabetes Month, which provides a perfect opportunity to remind us to look again at the associated diagnoses of diabetes for individuals with obesity.
Due to the shortages of obesity medications, some patients are turning to pharmacies that produce compounded versions of these medications.
New ICD-10 Codes for the Diagnosis of Obesity
In September 2023, the National Center for Health Statistics (NCHS) approved updated ICD-10-CM obesity codes and they go into effect on October 1, 2024.